Lilly’s Cialis Sales In China Unimpressive
This article was originally published in PharmAsia News
A year after Lilly entered China with erectile dysfunction drug Cialis (tadalafil) to compete with Pfizer's Viagra (sildenafil) and Bayer's Levitra (vardenafil), the latest entrant still lags behind the two rivals despite distributing its products to 5,000 drugstores. According to a principal drug chain, Cialis does not present any price advantage to retailers due to Lilly's strictly controlled high retail price. In addition, Viagra's dominant position and Pfizer's strong marketing support for its channels contribute to Cialis' poor take-up rate. Lilly China admits to Viagra having a first-entry advantage; however, the company is confident of Cialis' performance and believes it can compete effectively once the distribution channels are in place. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.